Biogen beats estimates as new medicines overtake multiple sclerosis business
Biogen Inc reported quarterly revenue and adjusted earnings that beat analysts’ expectations, helped by sales of newly acquired kidney and eye-disease drugs after its May US$5.6 billion Apellis deal. The company raised 2024 revenue guidance to mid-single-digit growth but lowered adjusted earnings to US$12–13 per share due to acquisition costs. Leqembi sales rose 15% to US$184 million.
How this was made
The 30-second read
Why it matters
The article’s key trading inputs are the beat versus expectations, the raised revenue outlook, and the lowered adjusted earnings guidance tied to acquisition costs and milestones. It also quantifies growth in several newer medicines, supporting a portfolio-mix narrative.
Market read
A concrete earnings and guidance update with quantified product growth and acquisition cost effects, likely driving near-term repricing around revenue durability versus adjusted earnings drag.
What to watch
Leqembi growth is described as roughly in line with expectations, so upside may rely more on the magnitude and durability of newer-product growth (Zurzuvae, Skyclarys) and on integration execution from Apellis and the announced RayThera deal.
Background
Biogen is repositioning from an aging multiple sclerosis franchise toward newer therapies via acquisitions, including Apellis (closed May) and a planned RayThera acquisition announced in June.
Ticker impact
Biogen beat quarterly estimates, raised full-year revenue outlook to mid-single-digit growth, and cut adjusted EPS guidance due to Apellis-related costs.
Near-term bias positive on revenue outlook and newer-drug momentum, with follow-through dependent on whether acquisition costs and milestones normalize.
The article provides specific guidance changes (revenue outlook raised, adjusted earnings guidance lowered) plus quantified product growth (Leqembi, Zurzuvae, Skyclarys) and notes Apellis revenue contribution, which together drive a clear earnings-quality debate.
Market effects
Reinforces the broader biotech read-through that diversification away from declining neurology franchises can re-rate earnings quality, but acquisition-cost drag remains a key risk.
Limited direct regional spillover beyond US large-cap biotech sentiment.
Moderate global relevance via Alzheimer’s and rare-disease commercial momentum and continued M&A-driven portfolio reshaping.
Counterpoint
The raised revenue outlook may be offset by structurally higher acquisition-related costs and milestone payments, making adjusted earnings guidance the more important near-term signal.
Key entities
- companyBiogen Inc
Reported quarterly results, raised revenue outlook, and cut adjusted earnings guidance due to acquisition-related costs and milestones.
- companyApellis Pharmaceuticals Inc
Acquisition closed in May; its drugs contributed nearly US$128 million in revenue during the remainder of the quarter.
- companyEisai Co
Partner for Leqembi; Leqembi sales grew 15% to US$184 million in the quarter.
- companyRayThera Inc
Announced acquisition in June for up to US$1 billion to expand immunology exposure.
